Novel treatments for acute myeloid leukemia #FIMM_UH
Joined October 2021
- Tweets 16
- Following 99
- Followers 81
- Likes 70
5 Photos and videos
Kontro Lab retweeted
This paper reports that authors identify molecular patterns linked to primary resistance to VEN–HMA therapy, including a higher BCL‑XL/BCL‑2 ratio and frequent TP53 mutations. These findings point to potential therapeutic strategies worth exploring
Read more in depth 👉bit.ly/3Lllpo9
1
9
33
2,507
Jan 15
Our latest @Hemasphere_EHA study from @FIMM_UH defines key signatures of #venetoclax hypomethylating agent #resistance in #AML and highlights strategies for targeting resistant disease.
Read more: doi.org/10.1002/hem3.70282
1
2
2
206
Kontro Lab retweeted
20 Oct 2025
Data presented at #ESMO25 by Dr Mika Kontro on the Macrophage reprogrammer #bexmarilimab plus azacitidine in myelodysplastic syndrome (BEXMAB)
@myESMO @OncoAlert @Daver_Leukemia @Dr_AmerZeidan
1
14
39
2,553
Kontro Lab retweeted
1/4
Capillary Sampling Enables Venetoclax Concentration Measurement in Acute Myeloid Leukaemia Within Academic Multicentre Trial
New study by @LabKontro and colleagues – study highlights 👇
1
1
180
25 Jan 2025
Ex vivo venetoclax sensitivity identified treatment responders and correlated with improved outcomes and prolonged survival. Groundbreaking results from the VenEx trial with the Finnish AML Group, @helsinkiuni and @FIMM_UH published now in @BloodJournal
24 Jan 2025
VenEx trial showed that ex vivo drug sensitivity is beneficial for selecting patients with R/R or sAML for venetoclax-azacitidine therapy. ow.ly/XpL350UMeJB #clinicaltrialsandobservations #myeloidneoplasia
3
2
14
1,193
Kontro Lab retweeted
29 Oct 2024
Drug sensitivity testing on leukemia cells can predict how patients with acute myeloid leukemia (AML) will respond to a new combination therapy.
New @LabKontro results allow treatments to be tailored to those who are most likely to benefit.
📰@HUS_fi:
hus.fi/en/newsroom/drug-sens…
ALT Tanja Ruokoranta, Ida Vänttinen and Mika Kontro working in a cell culture room wearing white laboratory coats. Photo: Ville Männikkö/HUS
1
2
12
664
Kontro Lab retweeted
29 Oct 2024
Leukemiasolujen lääkeherkkyystestauksella voidaan ennustaa akuuttia myelooista leukemiaa sairastavien potilaiden hoitovaste uudelle lääkeyhdistelmälle.
@LabKontro tulokset mahdollistavat hoidon kohdentamisen siitä eniten hyötyville potilaille.
📰@HUS_fi: hus.fi/ajankohtaista/laakehe…
ALT Tutkijat Tanja Ruokoranta, Ida Vänttinen ja Mika Kontro työskentelemassä soluviljelylaboratoriossa valkoiset takit päällä. Kuva: Ville Männikkö / HUS
2
15
585
12 Dec 2023
Dr. Mika Kontro from @KontroLab discussed the latest advances in functional screening during the Multi-Omics Driven Precision Hematology Scientific Symposia at #ASH23. The VenEx trial indicates the efficacy of ex vivo venetoclax testing for predicting VEN AZA responses in AML.
6
27
1,144
Kontro Lab retweeted
24 May 2023
Meet our K. Albin Johansson Cancer Researcher @hkuusanm. Heikki has a versatile background in translational laboratory studies and focuses now on novel treatments for acute myeloid leukemia in @LabKontro. Read more 👇syopainstituutti.com/researc…
3
20
915
Kontro Lab retweeted
26 Jan 2023
A clinical trial performed in Finland has shown that a drug sensitivity test performed on patient's own cells in laboratory conditions predicts patient's response to a new effective leukemia drug, venetoclax. The study was led by Mika Kontro & @hkuusanm.
helsinki.fi/en/hilife-helsin…
1
2
337
Kontro Lab retweeted
9 Jan 2023
1/ Excited to share our study with @ollidufva suggesting venetoclax resistance and BCL-XL dependence in erythroid/megakaryoblastic AML @BloodJournal
doi.org/10.1182/blood.202101…
4
20
81
17,718
16 Dec 2022
Our newest paper "Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia" is now published and accessible @Haematologica
haematologica.org/article/vi…
2
14
892
Kontro Lab retweeted
12 Dec 2022
Ex vivo venetoclax sensitivity predicts responses in both de novo and s/R/R AML patients @LabKontro #ASH22
2
13
12 Dec 2022
Excellent talk by @josephsaad95 on NAMPT inhibitors in AML with monosomy 7/del(7q) yesterday at #ASH22!
1
6
12 Dec 2021
Ex vivo drug sensitivity testing predicts venetoclax azacitidine treatment responses in AML. VenEx trial interim results presented at #ASH21
6
21